DelNS1-2019-nCoV-RBD-OPT

DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine candidate developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.


== References ==